Rua Bioscience Limited (NZX: RUA) Annual Results FY21

Monday 30th August 2021

Rua Bioscience announces its annual financial results for the 12 months ended 30 June 2021 (FY21). In FY21, Rua's focus has been on building solid foundations for growth – developing the partnerships, places, processes, and people it needs to create a sustainable medicinal cannabis business model.

Rua’s commitment to creating shareholder value has seen it working on two fronts - preparing to enter local and global medicinal cannabis markets by calendar year end 2021 / early 2022 and developing long-term opportunities across the medicinal cannabis value chain.

Outlook

Rua Bioscience is a pharmaceutical company aiming to lead the production of cannabinoid-derived medicines. The Company has a focused and realistic export strategy, with a clear path to revenue and a view extending along the medicinal cannabis value chain. Proceeds from the IPO continue to fund Rua Bioscience's next growth stage, building long-term resilience and accelerating growth.

Please see the links below for details

Rua Bioscience FY21 Annual Results Market Announcement

Investor Call Presentation

Financial Results Announcement FY21

Rua Bioscience Limited FY21 Financial Statements

Source: Rua Bioscience Limited

Comments from our readers

No comments yet